Welcome to the OniX OnPoint Newsletter, your weekly window into the cutting-edge world of biomedical innovation. At OniX Hub, we're committed to bridging the gap between groundbreaking research and real-world applications.

​

Summary of OniX OnPoint​

OniX OnPoint Issue 16 (Week 16, 2024) showcases significant advancements in immunotherapy and T-cell based therapeutic approaches across various sectors. The edition features groundbreaking sponsored projects from five countries, including novel neoantigen immunotherapy for brain tumors and innovative T-cell costimulatory antibody developments. The technology transfer section highlights five major developments from US institutions, focusing on anti-CD47 antibodies, CAR T cell therapy, and stem cell applications. The startup ecosystem is particularly active in the USA, with companies like Kineta and A-Alpha Bio leading innovations in immune-targeted therapies. Recent VC funding activities span across USA and Europe, with notable investments in Evommune ($115M Series C) and Axonis Therapeutics ($115M Series A). The news section covers breakthrough developments in immune checkpoint inhibitors and T-cell biology, emphasizing the dynamic evolution of cancer immunotherapy research and development across academic institutions, biotechnology companies, and pharmaceutical firms.​

​

OniX OnPoint is your trusted partner in navigating the healthcare and life sciences ecosystem. From licensing to partnerships and investment, we connect you with the right opportunities to drive progress.

We're committed to evolving this newsletter based on your feedback, always aiming to deliver the most relevant insights on biomedical innovation. Let's explore this week's most exciting developments in the field.